PMVP

NASDAQ

PMV Pharmaceuticals Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2020

News25/Ratings10

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function. It is also developing p53 R273H mutation and other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

News · 26 weeks21-67%

2025-10-262026-04-19

Mix1590d

Other5(33%)
SEC Filings5(33%)
Insider4(27%)
Leadership1(7%)

Latest news

25 items

1dSEC
SEC Form DEFA14A filed by PMV Pharmaceuticals Inc.
DEFA14A - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
1dSEC
SEC Form DEF 14A filed by PMV Pharmaceuticals Inc.
DEF 14A - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
1dPR
PMV Pharmaceuticals Announces Board Chair Transition
PRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced a leadership transition on its Board of Directors. Laurie Stelzer, who has served as a member of the Board since 2020, has been appointed Chair of the Board, succeeding Rich Heyman, Ph.D., effective at the Company's 2026 Annual Meeting of Stockholders on June 4, 2026 (the "Meeting"). Dr. Heyman's term as a member and Chair of the Board will expire at the Meeting, and Dr. Heyman will not stand for reelection. Ms. Stelzer brings more than 25
45dINSIDER
SEC Form 4 filed by Chief Financial Officer Carulli Michael
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
45dINSIDER
SEC Form 4 filed by General Counsel & COO Ticktin Robert
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
45dINSIDER
SEC Form 4 filed by Chief Development Officer Jalota Deepika
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
45dINSIDER
SEC Form 4 filed by President and CEO Mack David Henry
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
48dSEC
SEC Form S-8 filed by PMV Pharmaceuticals Inc.
S-8 - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
48dSEC
PMV Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
48dSEC
SEC Form 10-K filed by PMV Pharmaceuticals Inc.
10-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
48dPR
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew England Journal of Medicine published first-in-human rezatapopt data showing selective reactivation of mutant p53 in advanced solid tumorsRezatapopt New Drug Application submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027Cash, cash equivalents, and marketable securities of $112.9 million as of December 31, 2025 providing
50dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by PMV Pharmaceuticals Inc.
SCHEDULE 13D/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
56dPR
New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that results from the Phase 1, first-in-human portion of the ongoing Phase 1/2 PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation were published in the New England Journal of Medicine (NEJM). The publication provides a summary of the Phase 1 safety and efficacy results across 77 patients. The study published in NEJM entitled, "Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y2
65dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.
SCHEDULE 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
73dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.
SCHEDULE 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
162dSEC
SEC Form 10-Q filed by PMV Pharmaceuticals Inc.
10-Q - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
162dSEC
PMV Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
162dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.
SCHEDULE 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
176dINSIDER
President and CEO Mack David Henry exercised 220,643 shares at a strike of $1.37, increasing direct ownership by 96% to 451,109 units (SEC Form 4)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
178dINSIDER
Large owner Orbimed Advisors Llc sold $1,520,000 worth of shares (1,000,000 units at $1.52) (SEC Form 4)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
178dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by PMV Pharmaceuticals Inc.
SCHEDULE 13D/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
181dPR
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma34% overall response rate (ORR) observed among 103 evaluable patients across all cohorts with a median duration of response of 7.6 months46% ORR observed among 48 evaluable patients in ovarian cancer cohort with a median duration of response of 8.0 monthsRezatapopt New Drug Application submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027 PRINCETON, N.J., Oct.
182dSEC
SEC Form 144 filed by PMV Pharmaceuticals Inc.
144 - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
192dPR
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C mutation PRINCETON, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that two abstracts have been accepted for oral and poster presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22-26, 202
212dSEC
SEC Form SCHEDULE 13G filed by PMV Pharmaceuticals Inc.
SCHEDULE 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)